Gallus Immunotech

Gallus Immunotech was a life science tools company focused on the development and commercialization of egg-derived chicken antibodies, particularly IgY-based antibodies and related immunoreagents. The company sold primary and secondary antibodies, control immunoglobulins, IgY purification kits, and custom services such as peptide synthesis, antibody production, purification, and labeling for research use. Its differentiation was a humane antibody-generation approach based on harvesting antibodies from egg yolk rather than animal bleeding. Gallus served the research market rather than the therapeutic drug market, with products spanning infectious disease, toxin, and immunology-related targets. The company was acquired by Exalpha Biologicals on June 6, 2018, and the Gallus brand/products have since been integrated into the acquirer's portfolio.